Literature DB >> 35876019

Long-Term Leisure-Time Physical Activity Intensity and All-Cause and Cause-Specific Mortality: A Prospective Cohort of US Adults.

Dong Hoon Lee1, Leandro F M Rezende2, Hee-Kyung Joh1,3,4, NaNa Keum1,5, Gerson Ferrari6, Juan Pablo Rey-Lopez7,8, Eric B Rimm1,9,10, Fred K Tabung1,11, Edward L Giovannucci1,9.   

Abstract

BACKGROUND: The 2018 physical activity guidelines for Americans recommend a minimum of 150 to 300 min/wk of moderate physical activity (MPA), 75 to 150 min/wk of vigorous physical activity (VPA), or an equivalent combination of both. However, it remains unclear whether higher levels of long-term VPA and MPA are, independently and jointly, associated with lower mortality.
METHODS: A total of 116 221 adults from 2 large prospective US cohorts (Nurses' Health Study and Health Professionals Follow-up Study, 1988-2018) were analyzed. Detailed self-reported leisure-time physical activity was assessed with a validated questionnaire, repeated up to 15 times during the follow-up. Cox regression was used to estimate the hazard ratio and 95% CI of the association between long-term leisure-time physical activity intensity and all-cause and cause-specific mortality.
RESULTS: During 30 years of follow-up, we identified 47 596 deaths. In analyses mutually adjusted for MPA and VPA, hazard ratios comparing individuals meeting the long-term leisure-time VPA guideline (75-149 min/wk) versus no VPA were 0.81 (95% CI, 0.76-0.87) for all-cause mortality, 0.69 (95% CI, 0.60-0.78) for cardiovascular disease (CVD) mortality, and 0.85 (95% CI, 0.79-0.92) for non-CVD mortality. Meeting the long-term leisure-time MPA guideline (150-299 min/wk) was similarly associated with lower mortality: 19% to 25% lower risk of all-cause, CVD, and non-CVD mortality. Compared with those meeting the long-term leisure-time physical activity guidelines, participants who reported 2 to 4 times above the recommended minimum of long-term leisure-time VPA (150-299 min/wk) or MPA (300-599 min/wk) showed 2% to 4% and 3% to 13% lower mortality, respectively. Higher levels of either long-term leisure-time VPA (≥300 min/wk) or MPA (≥600 min/wk) did not clearly show further lower all-cause, CVD, and non-CVD mortality or harm. In joint analyses, for individuals who reported <300 min/wk of long-term leisure-time MPA, additional leisure-time VPA was associated with lower mortality; however, among those who reported ≥300 min/wk of long-term leisure-time MPA, additional leisure-time VPA did not appear to be associated with lower mortality beyond MPA.
CONCLUSIONS: The nearly maximum association with lower mortality was achieved by performing ≈150 to 300 min/wk of long-term leisure-time VPA, 300 to 600 min/wk of long-term leisure-time MPA, or an equivalent combination of both.

Entities:  

Keywords:  cardiovascular diseases; exercise; guidelines as topic; mortality

Mesh:

Year:  2022        PMID: 35876019      PMCID: PMC9378548          DOI: 10.1161/CIRCULATIONAHA.121.058162

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   39.918


  31 in total

1.  Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes.

Authors:  André La Gerche; Andrew T Burns; Don J Mooney; Warrick J Inder; Andrew J Taylor; Jan Bogaert; Andrew I Macisaac; Hein Heidbüchel; David L Prior
Journal:  Eur Heart J       Date:  2011-12-06       Impact factor: 29.983

2.  Test of the National Death Index.

Authors:  M J Stampfer; W C Willett; F E Speizer; D C Dysert; R Lipnick; B Rosner; C H Hennekens
Journal:  Am J Epidemiol       Date:  1984-05       Impact factor: 4.897

3.  Alternative dietary indices both strongly predict risk of chronic disease.

Authors:  Stephanie E Chiuve; Teresa T Fung; Eric B Rimm; Frank B Hu; Marjorie L McCullough; Molin Wang; Meir J Stampfer; Walter C Willett
Journal:  J Nutr       Date:  2012-04-18       Impact factor: 4.798

4.  Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals.

Authors:  S Chasan-Taber; E B Rimm; M J Stampfer; D Spiegelman; G A Colditz; E Giovannucci; A Ascherio; W C Willett
Journal:  Epidemiology       Date:  1996-01       Impact factor: 4.822

5.  Validity and Relative Validity of Alternative Methods of Assessing Physical Activity in Epidemiologic Studies: Findings From the Men's Lifestyle Validation Study.

Authors:  Claire H Pernar; Andrea K Chomistek; Junaidah B Barnett; Kerry Ivey; Laila Al-Shaar; Susan B Roberts; Jennifer Rood; Roger A Fielding; Jason Block; Ruifeng Li; Walter C Willett; Giovanni Parmigiani; Edward L Giovannucci; Lorelei A Mucci; Eric B Rimm
Journal:  Am J Epidemiol       Date:  2022-06-27       Impact factor: 5.363

6.  Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire.

Authors:  D Feskanich; E B Rimm; E L Giovannucci; G A Colditz; M J Stampfer; L B Litin; W C Willett
Journal:  J Am Diet Assoc       Date:  1993-07

7.  Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption.

Authors:  S Salvini; D J Hunter; L Sampson; M J Stampfer; G A Colditz; B Rosner; W C Willett
Journal:  Int J Epidemiol       Date:  1989-12       Impact factor: 7.196

8.  Test of the National Death Index and Equifax Nationwide Death Search.

Authors:  J W Rich-Edwards; K A Corsano; M J Stampfer
Journal:  Am J Epidemiol       Date:  1994-12-01       Impact factor: 4.897

9.  Association of Physical Activity Intensity With Mortality: A National Cohort Study of 403 681 US Adults.

Authors:  Yafeng Wang; Jing Nie; Gerson Ferrari; Juan Pablo Rey-Lopez; Leandro F M Rezende
Journal:  JAMA Intern Med       Date:  2021-02-01       Impact factor: 44.409

Review 10.  Do vigorous-intensity and moderate-intensity physical activities reduce mortality to the same extent? A systematic review and meta-analysis.

Authors:  Juan Pablo Rey Lopez; Angelo Sabag; Maria Martinez Juan; Leandro F M Rezende; Maria Pastor-Valero
Journal:  BMJ Open Sport Exerc Med       Date:  2020-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.